Display options
Share it on

Front Immunol. 2021 Oct 22;12:674080. doi: 10.3389/fimmu.2021.674080. eCollection 2021.

The Tonsil Lymphocyte Landscape in Pediatric Tonsil Hyperplasia and Obstructive Sleep Apnea.

Frontiers in immunology

Anna Carrasco, Isabella Sjölander, Aline Van Acker, Andy Dernstedt, Johan Fehrm, Mattias Forsell, Danielle Friberg, Jenny Mjösberg, Anna Rao

Affiliations

  1. Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
  2. Department of Surgical Sciences, Otorhinolaryngology-Head and Neck Surgery, Uppsala University, Uppsala, Sweden.
  3. Department of Clinical Microbiology, Section of Infection and Immunology, Umeå University, Umeå, Sweden.
  4. Department of Clinical Sciences, Intervention, and Technology, Karolinska Institutet, Stockholm, Sweden.

PMID: 34745084 PMCID: PMC8570126 DOI: 10.3389/fimmu.2021.674080

Abstract

Tonsil hyperplasia is the most common cause of pediatric obstructive sleep apnea (OSA). Despite the growing knowledge in tissue immunology of tonsils, the immunopathology driving tonsil hyperplasia and OSA remains unknown. Here we used multi-parametric flow cytometry to analyze the composition and phenotype of tonsillar innate lymphoid cells (ILCs), T cells, and B cells from pediatric patients with OSA, who had previous polysomnography. Unbiased clustering analysis was used to delineate and compare lymphocyte heterogeneity between two patient groups: children with small tonsils and moderate OSA (n = 6) or large tonsils and very severe OSA (n = 13). We detected disturbed ILC and B cell proportions in patients with large tonsils, characterized by an increase in the frequency of naïve CD27

Copyright © 2021 Carrasco, Sjölander, Van Acker, Dernstedt, Fehrm, Forsell, Friberg, Mjösberg and Rao.

Keywords: B cells; Innate lymphoid cell (ILC); T cells; Tonsils; obstructive sleep apnea

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

  1. Pharmacol Ther. 2018 May;185:34-49 - PubMed
  2. Nat Immunol. 2011 Sep 11;12(11):1055-62 - PubMed
  3. Int J Pediatr Otorhinolaryngol. 2015 Aug;79(8):1184-91 - PubMed
  4. Pediatrics. 2012 Apr;129(4):e857-65 - PubMed
  5. Pediatr Res. 2009 Oct;66(4):423-8 - PubMed
  6. Cell. 2015 Jul 2;162(1):184-97 - PubMed
  7. Immunol Lett. 2013 May;152(2):114-20 - PubMed
  8. Nature. 2009 Feb 5;457(7230):722-5 - PubMed
  9. Ulster Med J. 1960 Jun;29(1):59-63 - PubMed
  10. J Immunol. 2007 May 15;178(10):6624-33 - PubMed
  11. Expert Opin Investig Drugs. 2013 Jan;22(1):71-85 - PubMed
  12. Eur Arch Otorhinolaryngol. 2020 Jan;277(1):1-7 - PubMed
  13. Int Immunol. 2010 Jun;22(6):413-9 - PubMed
  14. J Exp Med. 2020 Oct 5;217(10): - PubMed
  15. Immunity. 2017 Dec 19;47(6):1142-1153.e4 - PubMed
  16. Nat Rev Immunol. 2013 Feb;13(2):145-9 - PubMed
  17. Nat Immunol. 2016 Apr;17(4):451-60 - PubMed
  18. Cell. 2018 Aug 23;174(5):1054-1066 - PubMed
  19. J Exp Med. 2008 Aug 4;205(8):1807-17 - PubMed
  20. Chest. 2014 May;145(5):1039-1045 - PubMed
  21. Immunol Cell Biol. 2021 Jan;99(1):49-64 - PubMed
  22. Cell. 2017 Mar 9;168(6):1086-1100.e10 - PubMed
  23. PLoS Pathog. 2016 Jun 15;12(6):e1005687 - PubMed
  24. Cochrane Database Syst Rev. 2020 Jan 17;1:CD007074 - PubMed
  25. PLoS One. 2016 May 02;11(5):e0154814 - PubMed
  26. Pediatr Clin North Am. 1989 Dec;36(6):1551-69 - PubMed
  27. Thorax. 2013 Oct;68(10):949-54 - PubMed
  28. PLoS Pathog. 2015 May 19;11(5):e1004894 - PubMed
  29. Cell Immunol. 2017 Nov;321:18-25 - PubMed
  30. Otolaryngol Head Neck Surg. 2010 Nov;143(5):680-4 - PubMed
  31. J Immunol. 2016 Mar 1;196(5):2051-2062 - PubMed
  32. Int J Pediatr Otorhinolaryngol. 2011 Mar;75(3):391-4 - PubMed
  33. Anat Embryol (Berl). 2001 Nov;204(5):367-73 - PubMed
  34. Nat Biotechnol. 2018 Dec 03;: - PubMed
  35. J Virol. 2000 Nov;74(21):9964-71 - PubMed
  36. JCI Insight. 2019 Apr 2;5: - PubMed
  37. Nat Rev Immunol. 2005 Mar;5(3):230-42 - PubMed
  38. J Exp Med. 2008 Aug 4;205(8):1797-805 - PubMed
  39. Proc Am Thorac Soc. 2008 Feb 15;5(2):242-52 - PubMed
  40. Blood. 2002 Mar 15;99(6):2154-61 - PubMed
  41. Cell Rep. 2017 Feb 14;18(7):1761-1773 - PubMed
  42. Eur J Clin Microbiol Infect Dis. 2011 Dec;30(12):1503-9 - PubMed
  43. Front Immunol. 2012 Apr 09;3:72 - PubMed
  44. Nat Immunol. 2004 Jan;5(1):64-73 - PubMed
  45. Sci Immunol. 2021 Feb 12;6(56): - PubMed
  46. Science. 2017 Oct 13;358(6360): - PubMed
  47. Front Immunol. 2019 Oct 18;10:2458 - PubMed
  48. Pediatrics. 2012 Sep;130(3):e714-55 - PubMed
  49. J Exp Med. 2005 Sep 19;202(6):783-91 - PubMed
  50. Immunol Lett. 2017 Nov;191:23-30 - PubMed
  51. JAMA Otolaryngol Head Neck Surg. 2018 Jul 1;144(7):594-603 - PubMed
  52. Immunity. 2017 Jan 17;46(1):148-161 - PubMed
  53. JCI Insight. 2017 Apr 20;2(8): - PubMed
  54. Int J Pediatr Otorhinolaryngol. 2019 Mar;118:84-89 - PubMed
  55. J Pediatr. 2017 Mar;182:177-183.e2 - PubMed
  56. J Immunol. 2006 Sep 15;177(6):3728-36 - PubMed
  57. J R Soc Med. 1990 Feb;83(2):104-7 - PubMed
  58. Sci Transl Med. 2019 Feb 6;11(478): - PubMed
  59. Nat Immunol. 2014 Apr;15(4):354-364 - PubMed

Publication Types